Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1964683 | 0.90 | ALDH1A1 (0.39) | SMN1; SMN2GAAKDM4EMEN1MAPT | |
| SCHEMBL15927847 | 0.85 | SMN1; SMN2 (0.35) | SMN1; SMN2GAAKDM4EMEN1MAPT | |
| SCHEMBL4291628 | 0.85 | SMN1; SMN2 (0.35) | SMN1; SMN2GAAKDM4EMEN1MAPT | |
| SCHEMBL3147640 | 0.85 | SMN1; SMN2 (0.35) | SMN1; SMN2GAAKDM4EMEN1MAPT | |
| SCHEMBL15927846 | 0.85 | SMN1; SMN2 (0.35) | SMN1; SMN2GAAKDM4EMEN1MAPT | |
| SCHEMBL7923032 | 0.83 | LMNA (0.36) | GAAALOX15POLBALDH1A1LMNA | |
| SCHEMBL28017152 | 0.83 | ALOX15 (0.35) | SMN1; SMN2GAAKDM4EMEN1MAPT | |
| SCHEMBL32676486 | 0.81 | SMN1; SMN2 (0.34) | SMN1; SMN2GAAKDM4EMEN1MAPT | |
| SCHEMBL8050020 | 0.80 | SMN1; SMN2 (0.33) | SMN1; SMN2GAAKDM4EMEN1MAPT | |
| SCHEMBL374081 | 0.79 | OPRM1 (0.41) | SMN1; SMN2GAAKDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582660-B1 | NEW CATHEPSIN S PROTEASE INHIBITORS, USEFUL IN THE TREATMENT OF E.G. AUTOIMMUNE DISORDERS, ALLERGY AND CHRONIC PAIN CONDITIONS | MEDIVIR UK LTD (GB) | 2015-07-22 | — | — | EP | disclosed |
| EP-2582660-B1 | NEW CATHEPSIN S PROTEASE INHIBITORS, USEFUL IN THE TREATMENT OF E.G. AUTOIMMUNE DISORDERS, ALLERGY AND CHRONIC PAIN CONDITIONS | MEDIVIR UK LTD (GB) | 2015-07-22 | — | — | EP | disclosed |
| US-20150025250-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD | 2015-01-22 | — | — | US | disclosed |
| US-8859605-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8859505-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8853281-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-10-07 | — | — | US | disclosed |
| US-8815809-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-08-26 | — | — | US | disclosed |
| EP-2509956-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2014-07-23 | — | — | EP | disclosed |
| EP-2509956-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2014-07-23 | — | — | EP | disclosed |
| EP-2752404-A1 | Cysteine protease inhibitors | Medivir UK Ltd (GB) | 2014-07-09 | — | — | EP | disclosed |
| US-20120283305-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2012-11-08 | — | — | US | disclosed |
| EP-2509957-A1 | CYSTEINE PROTEASE INHIBITORS | Medivir UK Ltd (GB) | 2012-10-17 | — | — | EP | disclosed |
| EP-2509956-A1 | CYSTEINE PROTEASE INHIBITORS | Medivir UK Ltd (GB) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011158197-A1 | NEW CATHEPSIN S PROTEASE INHIBITORS, USEFUL IN THE TREATMENT OF E.G. AUTOIMMUNE DISORDERS, ALLERGY AND CHRONIC PAIN CONDITIONS | MEDIVIR UK LIMITED (GB) | 2011-12-22 | — | — | WO | disclosed |
| US-20110312964-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2011-12-22 | — | — | US | disclosed |
| EP-2358692-A1 | CYSTEINE PROTEASE INHIBITORS | Medivir UK Ltd (GB) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011070539-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070541-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010070615-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010070615-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312964-A1 | CYSTEINE PROTEASE INHIBITORS | CTSS, CTSB, CTSV | SMN1; SMN2 4777/4885GAA 1271/4885KDM4E 4417/4885 |
| US-20150025250-A1 | CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTRB1 | SMN1; SMN2 4852/4885GAA 751/4885KDM4E 4295/4885 |
| US-20120283305-A1 | CYSTEINE PROTEASE INHIBITORS | CTSS, CTSB, CTRB1 | SMN1; SMN2 4521/4885GAA 588/4885KDM4E 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.